Current and future options for the treatment of chemotherapy-induced anaemia

Abstract

Chemotherapy-induced anaemia (CIA) is a significant source of morbidity in patients receiving treatment for cancer. There are three products currently available for the treatment of CIA: epoetin alfa, epoetin beta and darbepoetin alfa. Several organisations have published recommendations for the use of these agents. Several randomised, controlled trials have been conducted comparing the most popular dosing regimens of epoetin alfa and darbepoetin alfa, with conflicting results. Information regarding survival and adverse event data related to these agents continues to create debate. This review considers four new agents that are under development for the treatment of CIA.

Keywords::

• AMG114
• anaemia
• cancer chemotherapy
• CERA
• darbepoetin alfa
• epoetin alfa
• epoetin beta
• FG-2216
• Hematide™